H1 Blog

OCTOBER 30, 2023

By 2025, we can anticipate pretty significant shifts as AI continues to advance and integrate into various processes within the healthcare ecosystem. We predict that by 2025 we will see more widespread use of AI in recruiting patients for clinical trials. Post-Market Surveillance AI will analyze real-world data.

Science 59

Science Clinical Trials Trials Engineering 59

Perficient: Drug Development

DECEMBER 12, 2024

Welcome to 2025, where Salesforces Einstein GPT is transforming CRM as we know it. Personalized Marketing That Works Gone are the days of Dear Customer emails that nobody reads. Increases Revenue : Better lead management, smarter marketing, and proactive support all lead to higher sales and happier customers. Whats New in 2025?

Marketing 52

Marketing Production 52

Fierce BioTech

OCTOBER 17, 2024

They’ll explore the benefits of a holistic, patient-centered strategy that embraces diverse patient needs, driving more timely treatments and maximizing the impact of marketing efforts. How a comprehensive, patient-focused strategy can not only improve treatment outcomes but also optimize the financial return on marketing investments.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Marketing 52

Drug Channels

NOVEMBER 19, 2024

In Medicare Part D in 2025: Preferred Pharmacy Networks Fade in a Collapsing PDP Market , I documented the Inflation Reduction Act’s (IRA) disruption to Medicare Part D prescription drug plans (PDPs). As always, we provide you with a handy table for tallying each chain’s participation and changes from 2024 to 2025. Fein, Ph.D.,

Pharmacy 75

Pharmacy Marketing Drugs 75

BioPharma Drive: Drug Pricing

DECEMBER 19, 2023

A decision by European regulators to revoke approvals for five generic versions of Biogen's multiple sclerosis medicine helps cement the drug's monopoly there through early 2025.

Marketing 67

Marketing Regulations Drugs 67

Advarra

DECEMBER 17, 2024

As we look to 2025, Advarra thought leaders have compiled predictions and perspectives on key topics shaping the industry. This tension between cost containment and speed to market highlights the need for innovative solutions to streamline processes and consolidate technology systems all without sacrificing quality.

Clinical Research 52

Clinical Research Clinical Trials Trials Hospitals 52

Fierce BioTech

AUGUST 26, 2024

Pharma Marketing Trends: Key Takeaways from Digital Pharma East 2024 swheeler Mon, 08/26/2024 - 14:05 Thu, 09/26/2024 - 13:00 Resource Type Webinar Stephanie Butler Promotion Start Tue, 08/27/2024 - 14:15 Promotion End Thu, 02/27/2025 - 14:15 Duration 60 minutes Did you miss the buzz at Digital Pharma East 2024? Click here to login.

Marketing 52

Marketing Disease 52

Fierce BioTech

AUGUST 7, 2024

The Unfiltered Truth about AI & Pharma Marketing dwunderlin Wed, 08/07/2024 - 12:04 Wed, 09/04/2024 - 14:00 Resource Type Webinar Chris Cullmann Doug Barr Promotion Start Thu, 08/08/2024 - 15:00 Promotion End Sat, 02/08/2025 - 15:00 Duration 60 Minutes You need to know where artificial intelligence disrupts the pharmaceutical marketing norms.

Marketing 52

Marketing Pharmaceutical Companies Pharmaceuticals Production 52

The Pharma Data

FEBRUARY 8, 2021

Capital Markets Day 2021 provides a comprehensive update on Sanofi’s General Medicines and Consumer Healthcare strategies as well as Dupixent ® (dupilumab) and multiple new immunology assets. Key highlights to be presented at Capital Markets Day 2021. In 2020, Sanofi achieved around €1.7

Marketing 52

Marketing Clinical Trials Disease Vaccine 52

Conversations in Drug Development Trends

NOVEMBER 5, 2024

In preparation for World Orphan Drug Congress Europe, we interviewed Nathan Chadwick, Senior Director, Therapeutic Strategy Lead, Rare Disease, and Derek Ansel, MS, LCGC, Vice President, Therapeutic Strategy Lead, Rare Disease, to hear their insights into the current progress in rare disease research and their hopes for 2025.

Disease 52

Disease Clinical Trials Therapies Clinical Research 52

Perficient: Drug Development

NOVEMBER 15, 2024

Our experts are closely monitoring eight healthcare trends that are shaping industry leaders’ strategies in 2025. Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 And this year is especially interesting, as 2024’s U.S. billion by 2030.

Regulations 64

Regulations Compliance Production Nurses 64

Drug Channels

DECEMBER 13, 2024

This week, Im rerunning some popular posts while I prepare for todays Drug Channels Outlook 2025 live video webinar. (If Nonetheless, taxpayersprimarily via Medicare and Medicaidwill continue to dominate the employer-sponsored insurance market. If you sign up before 12 p.m. ET, you can attend the live event.) spending on healthcare.

Government 80

Government Specialty Pharmacies Pharmacy Drugs 80

Perficient: Drug Development

NOVEMBER 15, 2024

Our experts are closely monitoring eight healthcare trends that are shaping industry leaders’ strategies in 2025. Healthcare Trend #1: AI Disruption and Enablement Healthcare has seen a surge of interest in AI, with the market set to soar to $187.95 And this year is especially interesting, as 2024’s U.S. billion by 2030.

Regulations 52

Regulations Compliance Production Nurses 52

Drug Channels

NOVEMBER 7, 2024

Today’s guest post comes from Chris Dowd, Senior VP of Market Development at ConnectiveRx. Patient Support Programming in 2025 and Beyond. He then outlines three actions that should guide manufacturers' preparation. He then outlines three actions that should guide manufacturers' preparation. Read on for Chris’s insights.

Marketing 74

Marketing Drugs 74

Agency IQ

JULY 22, 2024

Updated EUDAMED roadmap projects mandatory use of some processes as early as December 2025 The new EUDAMED roadmap includes updates accounting for the recent amendments to the European medical device and diagnostics regulations, which allow for a phased rollout of the different functional modules of the database. OJEU) around July 2025.

Regulations 40

Regulations Marketing Clinical Trials Trials 40

BioPharma Drive: Drug Pricing

MAY 13, 2024

As commercial momentum builds, coverage incentives for the Medicare market are expected to favor biosimilars in 2025.

Biosimilars 57

Biosimilars Marketing 57

thought leadership

MAY 7, 2024

Are You Ready for Mandatory EU Health Technology Assessment Regulation (HTAR) Implementation Beginning January 2025? Pharmaceutical companies need to be prepared for the new European Health Technology Assessment Regulation (HTAR), which will take effect in January 2025.

Pharmaceutical Companies 59

Pharmaceutical Companies International Regulations Pharmaceuticals 59

Drug Patent Watch

DECEMBER 10, 2024

As patents for these biologics expire, the market for biosimilars is expanding rapidly, with significant implications for manufacturing technologies. The biosimilars market has been growing at an unprecedented rate, with global sales projected to reach over $60 billion by the end of the decade.

Biosimilars 79

Biosimilars Drugs Production Clinical Trials 79

Drug Channels

DECEMBER 9, 2024

This week, Im rerunning some popular posts while I prepare for Fridays Drug Channels Outlook 2025 live video webinar. The Humira biosimilar market just took another step forwardbut remains far from its ideal state. Express Scripts 2025 strategy will also drive biosimilar adoption, although its pricing strategy is more problematic.

Biosimilars 52

Biosimilars Production Marketing Drugs 52

The Pharma Data

MAY 18, 2021

It is anticipated that the combined moves will see over a billion toothpaste tubes per year become recyclable by 2025. We have made the commitment that 100% of our product packaging will be recyclable or reusable, where quality and safety permits, by 2025.This About Albéa. For further information please visit www.eplglobal.com.

Packaging 40

Packaging Science Marketing Production 40

Agency IQ

JANUARY 12, 2024

To kick off 2024, the British device regulator offered its medical device and IVD plans for this year and next, promising public action on the post-market surveillance regulation by mid-2024 and on the core regulations in late 2024 or early 2025. has done.

Regulations 59

Regulations Marketing 59

thought leadership

JUNE 4, 2024

Health technology developers (HTD) planning submission of a centralized Market Authorization Application (MAA) to the European Medicines Agency (EMA) should being preparing today for the implementation of the European Health Technology Assessment Regulation (HTAR).

Therapies 59

Therapies Regulations Production Marketing 59

Drug Channels

OCTOBER 21, 2024

Stop running in circles—It’s time to unlock proven strategies to propel market access. A program driven by market dynamics and led by champions of channel strategy, join your peers now to master the complexities of pharmacy and distribution models to accelerate market access—It's all happening December 10-12.

Specialty Pharmacies 83

Specialty Pharmacies Pharmacy Marketing Compliance 83

Fierce BioTech

SEPTEMBER 30, 2024

llam Mon, 09/30/2024 - 17:44 Resource Type Questex Event Fierce Pharma Engage Logo Color.png Tue, 04/29/2025 - 08:00 Content Channel Landing Page Url LEARN MORE Byline Presented by: Fierce Pharma & Fierce Biotech

Marketing 52

Marketing 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2023

On November 17th, CMS issued its final guidance on the Discount Program in which it responded to public comments and provided updated guidance for the Discount Program for 2025 and 2026. Manufacturers must sign the agreement by March 1, 2024, to participate in the 2025 plan year. Final Guidance at 2.

Compliance 105

Compliance Drugs Pharmacy Licensing 105

Fierce BioTech

SEPTEMBER 30, 2024

Fierce Biotech Week Fierce Biotech Week features insights from C-suite and executive leadership at biotech, mid-sized and large pharma companies on emerging trends and market dynamics that will help effectively prioritize R&D spend, optimize drug development and clinical operations, and navigate capital raising and partnering deals.

Pharma Companies 52

Pharma Companies Drug Development Marketing Drugs 52

Fierce BioTech

SEPTEMBER 30, 2024

llam Mon, 09/30/2024 - 18:06 Resource Type Questex Event FiercePharmaWeekAudience.jpg Mon, 09/08/2025 - 08:00 Content Channel Landing Page Url LEARN MORE Byline Presented by: Fierce Pharma & Fierce Biotech

Science 52

Science Production Marketing 52

Drug Channels

AUGUST 2, 2024

Today’s guest post comes from Stacey Little, Senior Vice President of Business Development and Marketing at AssistRx. To learn more, register for AssistRx's free three-part webinar series: Ahead of the Curve: Considerations for your 2025 Patient Support Program. Read on for Stacey’s insights.

Science 52

Science Marketing Drugs 52

The Pharma Data

NOVEMBER 4, 2020

5, 2020 /PRNewswire/ — Bactiguard presents updated financial targets for 2025 in connection with the company’s financial report for the third quarter of 2020. We now have a broader base and better market coverage in Europe , the Middle East , India , Southeast Asia and China. STOCKHOLM , Nov. Profitability. unchanged).

Licensing 52

Licensing Licensing Production Marketing 52

Drug Channels

SEPTEMBER 4, 2024

The Humira biosimilar market just took another step forward—but remains far from its ideal state. Below, we review the 18 products competing with Humira—including four private-label products marketed by in-house subsidiaries owned by CVS Health and Cigna.

Biosimilars 52

Biosimilars Production Marketing Drugs 52

National Institute on Drug Abuse: Nora's Blog

NOVEMBER 4, 2024

The drug market is rapidly changing, and people who actively use drugs and live this reality are best poised to provide information on the drug supply and its effects. Participants will meet virtually three or four times during 2025 and potentially early 2026 and will be compensated for their time during the meetings.

Science 91

Science Research Treatment Drugs 91

Fierce BioTech

AUGUST 22, 2024

All market signals indicate that the companies incorporating flexibility into their plans as a way to mitigate risks will be the successful ones. Through case studies and real-life examples, this webinar will explore how companies going global can: Make data-driven decisions on how to enter any given market. Launch efficiently.

Marketing 52

Marketing 52

The Pharma Data

FEBRUARY 22, 2022

Pfizer’s 2025 Opportunity Parity goals represent the company’s commitment to increasing representation of women and minorities at senior -level positions of the organization. Progress made from June 2019 to December 2021 towards different aspects of its 2025 Opportunity Parity Goals are highlighted below.

Government 52

Government Vaccine Science Therapies 52

LifeSciVC

JANUARY 16, 2024

The market for each target class likely asymptotes with the number of Pharma or large biotech who can clinically develop and commercialize such assets; thus, there is intense focus on the first handful of assets to market. Figure 2 shows pipelines across modalities for some of the competitive targets today.

Small Molecule 137

Small Molecule Trials Therapies Disease 137

The Pharma Data

SEPTEMBER 16, 2020

SLB linked to 2025 Patient Access Targets to increase patients reached in low- and middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagship Programs by 50%. Novartis is taking bold steps to increase patient reach in LMICs with its strategic innovative therapies by at least 200% by 2025.

Therapies 52

Therapies Regulations Government Disease 52

The Pharma Data

FEBRUARY 4, 2021

Capital Markets Day 2021 provides a comprehensive update on Sanofi’s General Medicines and Consumer Healthcare strategies as well as Dupixent ® (dupilumab) and multiple new immunology assets. Key highlights to be presented at Capital Markets Day 2021. In 2020, Sanofi achieved around €1.7

Marketing 52

Marketing Clinical Trials Disease Science 52

Codon

SEPTEMBER 29, 2024

2025 While the broader life sciences community had pivoted towards working on traditional mechanistic interpretations of biology, one graduate student still believed there was something to be learned using the models of life so celebrated previously. The 2025 genetic network paper fit that bill exactly. Subscribe to Asimov Press.

Engineering 133

Engineering Virus DNA Therapies 133